Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

13 results about "Amitriptyline" patented technology

This medication is used to treat mental/mood problems such as depression.

Novel alkaloid compound Oreonudine C as well as preparation method and application thereof

The invention discloses a compound with remarkable 5-hydroxytryptamine (5-HT) reuptake inhibition activity, a preparation method of the compound and application of the compound in preparation of anti-depression drugs. And the compound is a compound Oreonudine C. The invention further discloses a preparation method of the compound. The preparation method of the Oreonudine C comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, extracting with chloroform, and performing silica gel column chromatography, C18 ODS column chromatography and preparative high performance liquid chromatography on the chloroform extraction part to obtain the Oreonudine C. The invention further discloses a preparation method of the Oreonudine C. The preparation method of the Oreonudine C comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, and obtaining the Oreonudine C. In-vitro experiments show that the compound Oreonudine C remarkably inhibits reabsorption of 5-HT (the inhibition rate is 60.4%) in mouse hippocampal neuronal cells HT22, and the inhibition rate of the compound Oreonudine C is superior to that of a positive control drug amitriptyline (the inhibition rate is 53.6%). The invention provides an important candidate compound for developing efficient and novel antidepressant drugs.
Owner:HENAN UNIV OF CHINESE MEDICINE

Amitriptyline tablet coating device

The amitriptyline tablet coating device comprises a water chestnut type pot body, a breathable net is fixedly installed in the water chestnut type pot body, an inner cavity of the water chestnut type pot body is covered with the breathable net, and gaps are formed between the breathable net and the inner wall of the water chestnut type pot body at equal intervals; an air injection pipeline is further arranged in the inner cavity of the water chestnut type pot body, the air injection pipeline is kept static when the water chestnut type pot body rotates, the air injection pipeline extends from one end of the water chestnut type pot body to the other end of the water chestnut type pot body, and equidistant gaps are formed between the air injection pipeline and the ventilation net in the water chestnut type pot body; when the water chestnut type pot body rotates, tablets in the water chestnut type pot body form a relatively stable rolling face, the air spraying pipeline is parallel to the rolling face and arranged on the outer side of the rolling face, and the air spraying direction of an air spraying opening formed in the air spraying pipeline faces the rolling face and is perpendicular to the rolling face. The hot air system and the spraying system can be used at the same time, the coating efficiency is high, and the problem of mutual interference does not exist when the hot air system and the spraying system are used at the same time.
Owner:HENAN HUASHANG PHARM CO LTD

A drug for preventing or treating glioma, its preparation method and application

The present invention provides a drug for preventing or treating glioma, a preparation method and an application thereof. The drug comprises drug components: amitriptyline and doxorubicin. The present invention creatively uses the combined administration of doxorubicin and amitriptyline to synergistically resist glioma, achieving the effects of killing glioma and inhibiting the invasive growth of glioma. The present invention creatively discovers that the two drugs can synergistically inhibit the activity of glioma cells and can also significantly inhibit the secretion of exosomes by glioma cells. The combined administration combination has not been reported in the literature, and the synergistic effect of the two drugs exceeds expectations.
Owner:JIAXING UNIV

Application of amitriptyline and / or derivative thereof, mycobacterium tuberculosis inhibitor and pharmaceutical composition

PendingCN120204184AAntibacterial agentsOrganic active ingredientsNon tuberculosis mycobacteriumBiomedicine
The invention discloses application of amitriptyline and / or derivatives thereof, a mycobacterium tuberculosis inhibitor and a pharmaceutical composition, relates to the technical field of biological medicines, and discloses application of amitriptyline and / or derivatives thereof in preparation of an inhibitor for inhibiting mycobacterium tuberculosis and / or nontuberculous mycobacteria. According to the application disclosed by the invention, research finds that amitriptyline has a human macrophage level anti-tuberculosis effect and amitriptyline has an effect of inhibiting intracellular survival of mycobacterium tuberculosis and / or nontuberculous mycobacterium at a macrophage level for the first time, which indicates that amitriptyline has an application value as a drug for treating multidrug-resistant tuberculosis; the compound can be used as a novel antituberculous drug.
Owner:THE THIRD PEOPLES HOSPITAL OF SHENZHEN

Novel alkaloid compound Oreonudine G as well as preparation method and application thereof

The invention discloses a novel alkaloid Oreonudine G extracted from wild poppy and an application of the novel alkaloid Oreonudine G in preparation of an antidepressant drug. The preparation method of the Oreonudine G comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, extracting with chloroform, performing silica gel column chromatography on the chloroform extraction part, recrystallizing and the like to obtain the Oreonudine G. In-vitro pharmacological experiments show that the Oreonudine G can significantly inhibit reuptake of noradrenaline (NE), and the NE inhibition rate of the Oreonudine G is 43.0%, which is significantly higher than that of a positive drug amitriptyline (the inhibition rate is 35.5%). The invention provides an important candidate compound for developing efficient and novel antidepressant drugs.
Owner:HENAN UNIV OF CHINESE MEDICINE

Use of amitriptyline in acid sphingomyelinase deficiency, Gaucher disease, globoid cell leukodystrophy and Niemann-Pick type C

ActiveCN120617224BAmitriptylineDisease
The present application provides the application of amitriptyline in the treatment of acid sphingomyelinase deficiency, Gaucher disease, globoid cell leukodystrophy and Niemann Pick type C.
Owner:XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Methods of treating acute stress disorders and post-traumatic stress disorders

PendingCN119925322AOrganic active ingredientsNervous disorderAmitriptylineAcute Stress Disorder
The present invention relates to methods of treating post-traumatic stress disorders and acute stress disorders using a pharmaceutical composition comprising cyclobenzaprine, amitriptyline, or a pharmaceutically acceptable salt thereof. In particular, the present invention relates to methods of treating post-traumatic stress disorder, or one or more symptoms thereof, in a subject having undergone a traumatic event of less than or equal to about 9 years prior to initiation of treatment. The present invention also relates to methods of treating acute stress disorder or one or more symptoms thereof in a subject having undergone a traumatic event of less than or equal to about 1 month prior to initiation of treatment.
Owner:TONIX PHARMA HLDG LTD

Compositions for the treatment of chronic vulval and perineal pain and symptoms and conditions associated therewith

ActiveUS12521403B2Aerosol deliveryOintment deliveryTricyclic antidepressantAmitriptyline
Provides herein are compositions for the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith, comprising an estrogen, optionally estriol, and a tricyclic antidepressant, optionally amitriptyline, formulated for topical, transdermal or transmucosal administration. Also provided are methods for the production of said compositions and to uses thereof in the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith.
Owner:T&A PHARMA PTY LTD

COMPOSITIONS AND METHODS FOR MUCOSORPTION ABSORPTION

UndeterminedCY1125645T1AmitriptylineOral medication
The invention provides compositions and methods for administering therapeutic compounds, particularly cyclobenzaprine or amitriptyline, for absorption through the mucosa, wherein the compositions contain a basifying agent in addition to the therapeutic agent. The compositions and methods have a number of unexpected pharmacokinetic benefits over oral administration. Methods of treating fibromyalgia in a human subject are also provided.
Owner:TONIX PHARMA HLDG LTD

Method for preparing meconoquintupline and application of meconoquintupline in preparation of anti-depression drugs

The invention discloses a method for extracting alkaloid meconoquintupline (meconoquintupline) from wild opium poppy and application of the meconoquintupline (meconoquintupline) in preparation of an antidepressant drug. The meconopsis quintuplina alkali is prepared by the following steps: extracting the overground part of dried wild poppy by 95% ethanol, acidifying the extract, extracting by petroleum ether, adjusting the acid water layer to be alkaline by alkali liquor, extracting by chloroform, performing silica gel column chromatography on the chloroform extraction part, purifying by preparative high performance liquid chromatography, and the like, thereby obtaining the meconopsis quintuplina alkali. The meconopsis quintuplingensis alkali is obtained. Pharmacological experiments show that the meconopsis quintuplina alkali prepared by the method has a remarkable inhibition effect on reuptake of 5-hydroxytryptamine (5-HT) and noradrenaline (NE), and the inhibition rate is remarkably higher than that of a positive drug amitriptyline. The invention provides an important candidate compound for developing efficient and novel antidepressant drugs.
Owner:HENAN UNIV OF CHINESE MEDICINE

Novel alkaloid compound Oreonudine F as well as preparation method and application thereof

The invention discloses a compound with remarkable noradrenaline (NE) reuptake inhibition activity and application of the compound in preparation of an anti-depression drug. The compound is a compound Oreonudine F. The preparation method of the compound comprises the following steps: extracting an overground part of wild poppy by using 95% ethanol, acidifying an extract, extracting by using petroleum ether, adjusting an acid water layer to be alkaline by using alkali liquor, and extracting by using chloroform. The chloroform extraction part is subjected to silica gel column chromatography, C18 ODS column chromatography, preparative high performance liquid chromatography separation and the like, and the compound Oreonudine F is obtained. In-vitro activity test results show that the compound Oreonudine F significantly inhibits reabsorption of NE (the inhibition rate is 45.6%) in mouse hippocampal neuronal cells HT22, and the inhibition rate of the compound Oreonudine F is superior to that of a positive control drug amitriptyline (the inhibition rate is 35.5%). The invention provides an important candidate compound for developing efficient and novel antidepressant drugs.
Owner:HENAN UNIV OF CHINESE MEDICINE

Amitriptyline polymer micelle preparation as well as preparation method and application thereof

PendingCN121910721ANervous disorderAntipyreticAmitriptylineMedicinal chemistry
The invention belongs to the technical field of pharmaceutical preparations, and discloses a polymeric micelle preparation for treating neuropsychiatric diseases as well as a preparation method and application thereof. The preparation comprises amitriptyline, scoparone, SolutolHS15 and a hydrotropy auxiliary material HPMCK4M according to a specific ratio, the particle size of the micelle prepared by adopting a self-assembly method is 10-100 nm, the solubility of amitriptyline and scoparone can be remarkably improved, the synergistic effect of amitriptyline quick release and scoparone slow release is achieved, the micelle stability is excellent, the bioavailability is high, and the bioavailability is high. The medicine is suitable for treating neuropsychiatric diseases such as depression and anxiety, and is high in safety.
Owner:THE AFFILIATED HOSPITAL OF GUIZHOU MEDICAL UNIV